DK0773788T3 - Forbedrede præparater og fremgangsmåder til kemodenervering under anvendelse af neurotoxiner - Google Patents

Forbedrede præparater og fremgangsmåder til kemodenervering under anvendelse af neurotoxiner

Info

Publication number
DK0773788T3
DK0773788T3 DK96917968T DK96917968T DK0773788T3 DK 0773788 T3 DK0773788 T3 DK 0773788T3 DK 96917968 T DK96917968 T DK 96917968T DK 96917968 T DK96917968 T DK 96917968T DK 0773788 T3 DK0773788 T3 DK 0773788T3
Authority
DK
Denmark
Prior art keywords
neurotoxins
methods
admixtures
neurotoxin
compositions
Prior art date
Application number
DK96917968T
Other languages
English (en)
Inventor
L Bruce Pearce
Eric R First
Original Assignee
Allergan Inc
L Bruce Pearce
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc, L Bruce Pearce filed Critical Allergan Inc
Application granted granted Critical
Publication of DK0773788T3 publication Critical patent/DK0773788T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK96917968T 1995-06-06 1996-06-04 Forbedrede præparater og fremgangsmåder til kemodenervering under anvendelse af neurotoxiner DK0773788T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46576795A 1995-06-06 1995-06-06
PCT/US1996/008534 WO1996039167A1 (en) 1995-06-06 1996-06-04 Improved compositions and methods for chemodenervation using neurotoxins

Publications (1)

Publication Number Publication Date
DK0773788T3 true DK0773788T3 (da) 2003-09-01

Family

ID=23849078

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96917968T DK0773788T3 (da) 1995-06-06 1996-06-04 Forbedrede præparater og fremgangsmåder til kemodenervering under anvendelse af neurotoxiner

Country Status (8)

Country Link
US (1) US6087327A (da)
EP (1) EP0773788B1 (da)
AT (1) ATE239491T1 (da)
AU (1) AU6034396A (da)
DE (1) DE69627963T2 (da)
DK (1) DK0773788T3 (da)
ES (1) ES2198484T3 (da)
WO (1) WO1996039167A1 (da)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW574036B (en) 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
US6545126B1 (en) * 1999-03-18 2003-04-08 Wisconsin Alumni Research Foundation Chimeric toxins
DE19925739A1 (de) * 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US6337075B1 (en) 2000-01-11 2002-01-08 Allergan Sales, Inc. Methods for treating diabetes
US6261572B1 (en) 2000-01-11 2001-07-17 Allergan Sales, Inc. Method for treating a pancreatic disorder with a neurotoxin
US6143306A (en) * 2000-01-11 2000-11-07 Allergan Sales, Inc. Methods for treating pancreatic disorders
DK1398038T4 (da) * 2000-02-08 2011-03-28 Allergan Inc Lægemidler med botulinustoxin
US20030118598A1 (en) 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US8632785B2 (en) * 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US20060269575A1 (en) * 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
US20030138460A1 (en) * 2000-02-08 2003-07-24 Allergan, Inc Methods of treating animals with botulinum toxin pharmaceutical compositions
AU2001270219A1 (en) * 2000-06-28 2002-01-08 Ira Sanders Methods for using tetanus toxin for benificial purposes in animals (mammals)
US7273722B2 (en) * 2000-11-29 2007-09-25 Allergan, Inc. Neurotoxins with enhanced target specificity
US7115399B2 (en) * 2001-07-31 2006-10-03 Allergan, Inc. Pinna reflex assay
US20030113349A1 (en) * 2001-12-18 2003-06-19 Coleman William P. Topically applied clostridium botulinum toxin compositions and treatment methods
US7022329B2 (en) * 2002-02-25 2006-04-04 Allergan, Inc. Method for treating neurogenic inflammation pain with botulinum toxin and substance P components
US7691394B2 (en) * 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
US20040009180A1 (en) * 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
KR20050094817A (ko) * 2002-12-20 2005-09-28 보툴리늄 톡신 리서치 어쏘시에이츠, 인크. 개선된 약제학적 보툴리늄 독소 조성물
US7276244B2 (en) * 2004-02-12 2007-10-02 Philip Radovic Methods of treating abnormalities of the first metatarsophalangeal joint of the foot
US20050220821A1 (en) * 2004-03-31 2005-10-06 Allergan, Inc. Pressure sore treatment
US8323666B2 (en) 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
US8137677B2 (en) 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
US20070128226A1 (en) * 2005-12-01 2007-06-07 Philip Radovic Methods of treating pain associated with abnormalities of the first metatarsophalangeal joint of the foot
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
WO2009139739A1 (en) * 2006-02-14 2009-11-19 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions comprising a combination of botulinum toxin a and botulinum toxin b for treating conditions characterized by unwanted or excessive presynaptic neuronal activity or secretion
US8658391B2 (en) 2006-04-27 2014-02-25 Anterios, Inc. Assessment of the effects of topical administration of chemodenervating pharmaceuticals
US20080113051A1 (en) * 2006-11-13 2008-05-15 Allergan, Inc. Methods for alleviating tattoo pain
SG177184A1 (en) 2006-12-01 2012-01-30 Anterios Inc Amphiphilic entity nanoparticles
US9107815B2 (en) 2008-02-22 2015-08-18 Allergan, Inc. Sustained release poloxamer containing pharmaceutical compositions
KR101848095B1 (ko) * 2008-06-26 2018-04-11 안테리오스, 인코퍼레이티드 경피 운반
WO2010096134A1 (en) 2008-12-04 2010-08-26 Botulinum Toxin Research Associates, Inc. Extended length botulinum toxin formulation for human or mammalian use
US8129139B2 (en) 2009-07-13 2012-03-06 Allergan, Inc. Process for obtaining botulinum neurotoxin
US20120328701A1 (en) * 2011-01-24 2012-12-27 Anterios, Inc. Nanoparticle compositions, formulations thereof, and uses therefor
US9393291B2 (en) 2012-04-12 2016-07-19 Botulinum Toxin Research Associates, Inc. Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds
MX370929B (es) 2012-10-28 2020-01-08 Revance Therapeutics Inc Composiciones y usos de las mismas para el tratamiento seguro de la rinitis.
US9901627B2 (en) 2014-07-18 2018-02-27 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
KR102480965B1 (ko) 2016-09-13 2022-12-26 알레간 인코포레이티드 안정화된 비단백질 클로스트리듐 독소 조성물
MX2019005833A (es) 2016-11-21 2019-10-30 Eirion Therapeutics Inc Administracion transdermica de agentes grandes.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5401243A (en) * 1990-08-21 1995-03-28 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
US5183462A (en) * 1990-08-21 1993-02-02 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
WO1994000481A1 (en) * 1992-06-23 1994-01-06 Associated Synapse Biologics Pharmaceutical composition containing botulinum b complex
US5562907A (en) * 1993-05-14 1996-10-08 Arnon; Stephen S. Method to prevent side-effects and insensitivity to the therapeutic uses of toxins
AU683275B2 (en) * 1993-06-10 1997-11-06 Allergan, Inc. Multiple botulinum toxins for treating neuromuscular disorders and conditions
DE122009000066I2 (de) * 1993-06-10 2010-12-30 Allergan Inc Behandlung von neuromuskulären Störungen und Zuständen mit verschiedenen botulinen Serotypen
US5512547A (en) * 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation

Also Published As

Publication number Publication date
ES2198484T3 (es) 2004-02-01
US6087327A (en) 2000-07-11
AU6034396A (en) 1996-12-24
ATE239491T1 (de) 2003-05-15
WO1996039167A1 (en) 1996-12-12
EP0773788A1 (en) 1997-05-21
EP0773788B1 (en) 2003-05-07
DE69627963T2 (de) 2004-03-04
DE69627963D1 (de) 2003-06-12

Similar Documents

Publication Publication Date Title
DK0773788T3 (da) Forbedrede præparater og fremgangsmåder til kemodenervering under anvendelse af neurotoxiner
WO2002040506A3 (en) Modified clostridial neurotoxins with altered biological persistence
DK0544777T3 (da) Enzymatisk detergentsammensætning og fremgangsmåde til enzymstabilisering
DE69940439D1 (de) Streptococcus pneumoniae proteine und immunogene fragmente für impstoffe
Ohishi Activation of botulinum C2 toxin by trypsin
Brown et al. Inhibition of protein synthesis by Shiga toxin: activation of the toxin and inhibition of peptide elongation
Assakura et al. Comparison of immunological, biochemical and biophysical properties of three hemorrhagic factors isolated from the venom of Bothrops jararaca (jararaca)
WO2001078760A3 (en) Method for treating pain by peripheral administration of a neurotoxin
WO2002008268A3 (en) Leucine-based motif and clostridial neurotoxins
ES2123951T3 (es) Formulaciones liofilizadas del factor de celulas pluripotenciales.
WO2001026736A3 (en) Intraspinal compositions containing botulinum toxin for treating pain
DE69319740D1 (de) Verbesserte synthese von polymer-bioaktiven-konjugaten
DK0921785T3 (da) Kombination af syreproteaseenzymer og sure puffere og anvendelser deraf
DE60007001D1 (de) Neurotoxine zur behandlung von pankreatischen krankheiten
GEP20043200B (en) Therapeutic Agent Comprising a Botulinum Neurotoxin
DK0778781T3 (da) Pneumokok-polysaccharid-rekombinant pneumolysin-konjugat-vacciner til immunisering mod pneumokokinfektioner
MY129998A (en) Saccharin derivative proteolytic enzyme inhibitors
AU4245097A (en) Multivalent vaccine for (clostridium botulinum) neurotoxin
WO2001082961A3 (en) Methods for treating bone tumors
Worthington et al. Physical changes in the epsilon prototoxin molecule of Clostridium perfringens during enzymatic activation
FI942625A0 (fi) Peptidisiä fosfinyylioksimetyyliketoneja interleukiini-1beta-muuttuvan entsyymin inhibiittoreina
DE69533673D1 (de) Behandlung und prävention von helicobacter-infektionen
FR2773478B1 (fr) Composition de teinture d'oxydation des fibres keratiniques et procede de teinture mettant en oeuvre cette composition
NO955258L (no) Medisinsk anvendelse av enzymer
DK2359853T3 (da) Farmaceutiske sammensætninger og fremgangsmåder, der er anvendelige til at modulere antiogenese